Spasmodic torticollis associated with sertraline in a child and an adolescent

Ayaydın H, Bozkurt H. Spasmodic torticollis associated with sertraline in a child and an adolescent. Turk J Pediatr 2015; 57: 109-111.Movement disorders or extrapyramidal symptoms (EPS) associated with selective serotonin reuptake inhibitors (SSRIs) have been reported. Although akathisia was found to be the most common EPS, and fluoxetine was implicated in the majority of the adverse reactions, there were also cases with EPS due to sertraline treatment. We present a child and an adolescent who developed torticollis (cervical dystonia) after using sertraline. To our knowledge, the child case is the first such report of sertraline-induced torticollis, and the adolescent case is the third in the literature

PDF

___

Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148-156.

Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 741-748.

Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6: 119-126.

Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S (eds). Movement Disorders (2nd ed). London: Butterworths; 1987: 332-358.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.

Sarısoy S, Özyürek H, Sarısoy G. Oromandibular dystonia associated with sertraline in an adolescent patient. Bulletin of Clinical Psychopharmacology 2012; 22: 83-85.

Yazıcı KU, Percinel I. [Cervical dystonia associated with sertraline in an adolescent case]. [Article in Turkish] Firat Med J 2014; 19: 53-55.

Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454.

Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692-698.

Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466-476.

Soubrié P, Reisine TD, Glowinski J. Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using the push-pull cannula technique. Neuroscience 1984; 13: 605-625.

Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 1995; 281: 255-261.

Saller CF, Czupryna MJ, Salama AI. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990; 253: 1162-1170.

Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995; 15: 821-829.

Vandel P, Bonin B, Vandel S, Sechter D, Bizouard P. CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects. Med Hypotheses 1996; 47: 439-442.

Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192-197.

Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377-389.

Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17: 75-79.